Confo Therapeutics raise €30m in Series A financing

Confo Therapeutics has a dual business model. With revenues from drug discovery partnerships, the company has built a portfolio of first-in-class preclinical programmes based on its proprietary Confo^® technology, which derive highly specialised camelid single domain antibodies (ConfoBodies^TM) that stabilize the druggable signaling conformation of G-protein coupled receptors (GPCRs) to enable screening for pathway-selective agonists.

According to the 2015 VIB spin-out, the funds will be used to accelerate both arms of Confo's business. Currently, the company has contracts with Roche and Lundbeck. CONFO^® technology was developed by Prof. Jan Steyaert and his team (VIB/Vrije Universiteit Brussel). It stabilises GPCRs, which are like on-off switches, in their active functional state. Back in 2015, Confo Therapeutics started with a team of six employees, under the supervision of Stephane van Rooijen, formerly from Genzyme and Viropharma.